A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

ClinicalTrials.gov ID: NCT07498426

Public ClinicalTrials.gov record NCT07498426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Placebo-controlled, Parallel Group, Double-blind Study to Evaluate the Efficacy and Safety of NIO752 in Participants With Progressive Supranuclear Palsy Followed by an Open Label Extension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.

Study identification

NCT ID: NCT07498426
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 300 participants

Conditions and interventions

Conditions

Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

Interventions

NIO752 Other
Placebo Drug

Other · Drug

Eligibility (public fields only)

Age range: 41 Years to 81 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 3, 2026 (Actual)
Primary completion: Jul 20, 2029 (Estimated)
Completion: Jul 18, 2031 (Estimated)
Last update posted: Oct 15, 2026

2026 – 2031

United States locations

U.S. sites: 9
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
Mayo Clinic Arizona	Scottsdale	Arizona	85259	Recruiting
Univ of California San Francisco	San Francisco	California	94158	Recruiting
CenExcel Rocky Mtn Clin Research	Englewood	Colorado	80113	Recruiting
Parkinsons Disease and Movement Disorders Center of Boca Raton	Boca Raton	Florida	33486	Recruiting
Mayo Jacksonville	Jacksonville	Florida	32224	Recruiting
University of Kentucky - C201 Clinic	Lexington	Kentucky	40536	Recruiting
Ochsner Clinic Foundation	New Orleans	Louisiana	70121	Recruiting
Mayo Clinic	Rochester	Minnesota	55905	Recruiting
Central TX Neuro Consultants P A	Round Rock	Texas	78681	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07498426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 15, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07498426 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →